|
|
Profile
|
Delegates :
Takao Hamakubo |
|
Incorporated :
September 26 , 2019 |
Paid in Capital :
100 Million yen |
Employees :
7 人 |
Address :
Koujimachi 3-5-4 Koujimachi Intelligent bil. B-1, Chiyoda-ku TOKYO
〒102-0083
|
TEL/FAX :
+81-3-5452-5742 / |
URL：
https://photoq3.com |
Attachment :
|
Mission/Background :
PhotoQ3 Inc. is a biotech startup dedicated to developing gentle and effective treatments for diseases with no existing cure. Our core technology, iTAP (intelligent Targeted Antibody Phototherapy), combines immunotoxin (antibody-toxin conjugates) with photodynamic therapy to selectively destroy cancer cells. We aim to contribute to society and patients by offering innovative, minimally invasive cancer treatments. Our business model is based on academic-industry collaboration, including partnerships with the University of Tokyo and Nippon Medical School. |
|
Technology & Business
|
iTAP is a novel therapeutic platform that utilizes antibody-toxin conjugates and photosensitizer activated by light energy. This method allows for precise targeting and destruction of cancer cells with minimal side effects. The treatment involves immunotoxin and photosensitizer injection followed by laser irradiation, enabling outpatient procedures. Our pipeline includes therapies for lung cancer, brain tumors, and ovarian cancer, with the goal of developing day-treatment options for patients.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
iTAP Therapy for Cancer
|
Preclinical
|
Antibody-based phototherapy for selective cancer cell destruction
|
Preparation for clinical trial
|
Immunotoxin Production Technology
|
Discovery
|
High-quality mass production of antibody-toxin conjugates
|
Standardization and scale-up
|
Lung Cancer Pipeline
|
Preclinical
|
iTAP-based therapy targeting lung cancer
|
Phase 1 trial preparation
|
Brain Tumor Pipeline
|
Discovery
|
iTAP-based therapy for brain tumors
|
Start of preclinical studies
|
Ovarian Cancer Pipeline
|
Discovery
|
iTAP-based therapy for ovarian cancer
|
Pipeline expansion
|
|
Highlights
|
In August 2025, PhotoQ3 filed a patent for a novel immunotoxin production method. The company joined the AMED project and exhibited at JHVS2025.
Mouse zenograft tumor models for lung cancer therapy were already completed, and preparations for GMP-grade drug manufacturing are underway.
|
|
Hot news
|
As our lung cancer therapy pipeline, mouse zenograft tumor models were successfully completed.
We are actively engaging with potential partners to accelerate clinical development and global expansion.
|
|
Alliance strategy
|
We are seeking partners for joint development of our iTAP-based cancer therapies, especially in the lung cancer pipeline. We welcome collaborations with pharmaceutical companies interested in licensing or co-developing our innovative treatment platform.
|
|
|